Prior art — US Patent 12569491

To search the USPTO database for patent 12569491, I would use the Patent Public Search tool on the USPTO website. I would enter the patent number "12569491" into the search field, specifically looking for utility patents, and execute the search.

To identify the most relevant prior art for US patent 12569491, I would then examine the "Cited By" or "References Cited" section of the patent document itself once retrieved from the USPTO database. This section typically lists the prior art references considered by the patent examiner during prosecution.

For each of those cited references, to determine potential anticipation under 35 U.S.C. § 102, I would follow these steps:

Retrieve Full Citation and Dates: Obtain the full patent or publication number, publication date, and filing date for each cited reference.
Brief Description: Read the abstract, claims, and relevant sections of the specification of each cited reference to understand its disclosed invention.
Analyze Anticipation under 35 U.S.C. § 102: According to 35 U.S.C. § 102, a claim is anticipated if "each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference." This means the prior art must disclose exactly what is claimed, arranged as in the claim, without any need for combining multiple disclosures or making modifications. A species disclosed in the prior art can anticipate a later claim to a genus that includes that species.

For each claim (1, 11, 13, 15) of US12569491B2, I would compare its elements to the disclosure of each individual prior art reference.
- For Claim 1 (Method of treating TART/OART with a CRF1 antagonist): I would look for prior art that explicitly or inherently discloses administering a CRF1 antagonist (or a pharmaceutically acceptable salt thereof) to a subject to treat or prevent TART or OART.
- For Claim 11 (Pharmaceutical composition with compound of Formula (I)): I would search for prior art that explicitly or inherently discloses a pharmaceutical composition containing the compound of structural Formula (I) (or its pharmaceutically acceptable salt) in the specified dosage range (5 mg to 1000 mg) with a pharmaceutically acceptable excipient. Since the specific chemical structure of Formula (I) is critical and was not provided in text, I would need to visually compare the structure in the original patent document to any chemical structures in the prior art.
- For Claim 13 (Method of treating TART/OART with an additional chemotherapeutic agent): I would examine prior art for disclosures of treating TART or OART by administering one of the listed additional chemotherapeutic agents (glucocorticoid, mineralocorticoid, ACAT1 inhibitor, or anti-androgen).
- For Claim 15 (Method combining CRF1 antagonist with surgery/radiation): I would look for prior art that discloses administering a CRF1 antagonist of structural Formula (I) (or its pharmaceutically acceptable salt) for TART or OART, in combination with surgical resection or radiation therapy, where the timing of these treatments (prior to, after, or concurrent) is also disclosed.

Without access to the USPTO database at this moment to perform a live search of the "References Cited" section of US12569491B2, I cannot provide the specific list of prior art citations and their detailed analysis. The provided information about US12569491B2 does not include its cited prior art.